Busch N, Holzbach R T
Gastrointestinal Research Unit, Cleveland Clinic Foundation, Ohio 44195-5218.
Hepatology. 1990 Sep;12(3 Pt 2):195S-198S; discussion 199S.
The idea that biliary proteins somehow inhibit nucleation/crystal growth of cholesterol crystals in supersaturated human biles is not new, and some supportive, albeit preliminary, evidence has already been provided for this. Progress in purification of biliary effector proteins has been slow and hindered by the lack of a sensitive and convenient assay method. The formidable problems of removing large amounts of both mucin and lipids from the samples before isolation of biliary proteins has constituted another major obstacle. Recently, the combination of a newly developed nucleation and crystal growth assay and the systematic use of lectin affinity chromatography has enabled rapid progress to be made. With these approaches, glycoprotein fractions containing primarily inhibiting activity and other fractions containing primarily promoting activity have been isolated from normal human biles. Thus these opposing activities can coexist and influence a balance of effects potentially defining the presence of health or disease. The most recent studies have led to the isolation of a single glycoprotein having an extremely potent crystal growth-inhibiting activity.
胆汁蛋白以某种方式抑制过饱和人胆汁中胆固醇晶体的成核/晶体生长这一观点并不新鲜,并且已经有一些支持性的(尽管是初步的)证据。胆汁效应蛋白的纯化进展缓慢,并且由于缺乏灵敏且便捷的检测方法而受到阻碍。在分离胆汁蛋白之前,从样品中去除大量粘蛋白和脂质这一艰巨问题构成了另一个主要障碍。最近,新开发的成核和晶体生长检测方法与凝集素亲和色谱法的系统应用使得取得了快速进展。通过这些方法,已从正常人胆汁中分离出主要含有抑制活性的糖蛋白组分和主要含有促进活性的其他组分。因此,这些相反的活性可以共存,并影响可能决定健康或疾病存在的效应平衡。最近的研究已导致分离出一种具有极强晶体生长抑制活性的单一糖蛋白。